# Burden-matched funding for trials led in low- and middle-income countries

Source: https://onco.cc/ideas/idea-fund-lmic-burden-match/  
OnCo record `idea-fund-lmic-burden-match` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Seven in ten cancer deaths are in poorer countries, yet almost all trials happen in rich ones. Funders would commit a share of money for trials designed and led where the burden is.

## Summary

The largest cancer research funders commit a fixed fraction (say 15%) of their trials budget to studies whose principal investigator and majority of sites are in low- and middle-income countries, targeting cancers and questions that matter there: cervical cancer treatment with limited radiotherapy, oesophageal squamous cell carcinoma, hepatocellular carcinoma from hepatitis B, hypofractionation and shorter regimens, low-cost generics. Precedents include Tata Memorial's trials that changed global practice on low-dose immunotherapy and neoadjuvant chemotherapy in head and neck cancer at a fraction of Western trial costs.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A burden-matched commitment produces at least ten practice-changing phase 3 results relevant to LMIC settings within a decade at a per-patient cost under a third of comparable high-income trials, and doubles the LMIC share of registered interventional oncology trials.
- Rationale: Trials in India, Brazil and China have shown that large, pragmatic, low-cost phase 3s are feasible and change guidelines; the limiting factor is core funding for trial units rather than science. Results generalise upward more often than down: hypofractionation and de-escalation findings from LMIC trials have been adopted in rich countries.
- Proposed test: Two funders pool a pilot fund of tens of millions, award competitively to LMIC-led trial units, and audit after five years for trials completed, guideline citations and cost per patient compared with the funders' other trials.
- Maturity: speculative
- Actor: philanthropy

## Sources

- Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012): https://doi.org/10.1186/1471-2407-12-526

## Connected records

- ideas: [A Global Fund for cancer care in low- and middle-income countries](https://onco.cc/ideas/idea-fund-global-cancer-fund/), [Blended finance and a low-cost linac to close the global radiotherapy gap](https://onco.cc/ideas/idea-fund-lmic-radiotherapy-finance/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- institutions: [Hospital Israelita Albert Einstein](https://onco.cc/institutions/einstein-sao-paulo/), [Sun Yat-sen University Cancer Center](https://onco.cc/institutions/sysucc/), [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- people: [Carlos Barrios](https://onco.cc/people/barrios-carlos/), [Rajendra Badwe](https://onco.cc/people/badwe-rajendra/), [Sudeep Gupta](https://onco.cc/people/gupta-sudeep/)
- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- key papers: [Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials](https://onco.cc/key-papers/paper-sun-bmc-cancer/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-lmic-burden-match.json